Please login to the form below
Amgen's Mvasi is first FDA-approved cancer biosimilar
Offers prospect of lower-cost alternative to Roche's Avastin
Sandoz says Humira biosimilar clears clinical hurdle
Its drug matches the safety and efficacy of AbbVie’s plaque psoriasis blockbuster
Lilly's abemaciclib data leaves potential uncertain
MONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali
Novartis scores but Roche misses in melanoma trials
Phase III trial combo success for Tafinlar/Mekinist “unprecedented”
Teva poaches Lundbeck's Schultz as new CEO
Shares in Lundbeck fall as two senior posts become vacant
Prix Galien opens for entries with new award
2018 programme will include new medical technology category
AZ buoyed by latest lung cancer data at ESMO
Data from separate Tagrisso and Imfinzi trials show superior PFS among patients
Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive
US drug maker to slash its workforce by 8.5%
BMS' Opdivo and Yervoy ace kidney cancer trial
Combined checkpoint inhibitors show improved survival versus standard therapy
Riding the wave of digital disruption
The challenges and rewards of meeting consumer expectations
-
Real-world evidenceCompanies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future
-
The future of biotechWhat impact will the sector, and its R&D performance, have on pharma?
-
Takeda can't sway NICE on oral myeloma therapy NinlaroDrug not recommended for NHS use in England and Wales
-
Cellectis floored by patient death in CAR-T trialFDA puts two cancer immunotherapy trials on hold
-
J&J expands its TB research programmePartners with Indian groups CSIR and IMTECH to develop new treatments
-
Merck & Co's anacetrapib data fails to generate much excitementTreatment proves unable to reduce a composite outcome of major atherosclerotic events
-
Biogen says trial extension data keep Alzheimer's drug on trackReleases updated results from the PRIME trial of anti-amyloid drug aducanumab
-
Intriguing data with Juno's new CAR-T therapySuggests a long treatment effect from the biotech's JCAR017 candidate
-
Astellas extends phase III programme for Rydapt rival gilteritinibJapanese group hopes its AML drug will soon compete with Novartis' recently-approved treatment
-
Cancer Research UK's Karen Vousden to join BMS boardShe will also serve on the pharma firm's Science and Technology Committee
-
Therachon appoints Christian Meyer as chief medical officerHe succeeds Maarten Kraan who remains as an advisor
-
Novartis appoints Shaun Coughlin to lead its US biomedical research instituteThe renowned academic joins as the pharma firm's global head of cardiovascular and metabolism
-
Constellation Pharmaceuticals strengthens management team
Appointments include Adrian Senderowicz as chief medical officer
-
NDA bolsters its senior team
Hires Eva Lilienberg, Christine Chirdo and Barbara Clendenen
Latest research appointments
Featured jobs
- Director of Scientific and Editorial Services
-
Great salary and benefits - Circa 100K
-
Principal Medical Writer
-
Great salary and benefits
-
Medical Writer
-
Competitive Salary
- Director of Rare Diseases, Healthcare Agency, London
-
Excellent Package
-
Programme Director
-
Salary TBC
- Senior Medical Writer, Medical Communications, London
-
Excellent package
- Senior Account Manager/ Account Director – Pharma and Life Scien...
-
Competitive Salary
- Editorial Director, Medical Communications, London
-
Excellent package
-
Account Director
-
Salary TBC
- Principal Medical Writer, Medical Communications, London
-
Excellent package
- Account Executive - Pharma and Life Sciences Brighton or Maccles...
-
Competitive Salary
Subscribe to our email news alerts
- Novartis looks outside pharma for digital transformation
- Roche faces prospect of second Rituxan biosimilar in US
- GSK preps COPD filing for asthma pioneer Nucala
- Sandoz says Humira biosimilar clears clinical hurdle
- Amgen's Mvasi is first FDA-approved cancer biosimilar
- Novartis scores but Roche misses in melanoma trials
PMHub
Frontera
Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...
Latest intelligence
- Biosimilars: what the future looks like
- Biosimilars: what the future looks like...
- Tightening medical device safety
- European legislators seek to reduce patient exposure to safety risks...
- Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
- ...
Quick links
Infographics
